Stimulating Innate Immunity to Enhance Radiation Therapy–Induced Tumor Control

Jason R. Baird, Arta M Monjazeb, Omid Shah, Heather McGee, William J Murphy, Marka R. Crittenden, Michael J. Gough

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Novel ligands that target Toll-like receptors and other innate recognition pathways represent a potent strategy for modulating innate immunity to generate antitumor immunity. Although many of the current clinically successful immunotherapies target adaptive T-cell responses, both preclinical and clinical studies suggest that adjuvants have the potential to enhance the scope and efficacy of cancer immunotherapy. Radiation may be a particularly good partner to combine with innate immune therapies, because it is a highly efficient means to kill cancer cells but may fail to send the appropriate inflammatory signals needed to act as an efficient endogenous vaccine. This may explain why although radiation therapy is a highly used cancer treatment, true abscopal effects—regression of disease outside the field without additional systemic therapy—are extremely rare. This review focuses on efforts to combine innate immune stimuli as adjuvants with radiation, creating a distinct and complementary approach from T cell–targeted therapies to enhance antitumor immunity.

Original languageEnglish (US)
Pages (from-to)362-373
Number of pages12
JournalInternational Journal of Radiation Oncology Biology Physics
Volume99
Issue number2
DOIs
StatePublished - Oct 1 2017

Fingerprint

immunity
Innate Immunity
tumors
cancer
Radiation
Immunotherapy
Immunity
therapy
radiation
vaccines
Neoplasms
Toll-Like Receptors
stimuli
radiation therapy
Radiotherapy
Therapeutics
Vaccines
Ligands
T-Lymphocytes
ligands

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Stimulating Innate Immunity to Enhance Radiation Therapy–Induced Tumor Control. / Baird, Jason R.; Monjazeb, Arta M; Shah, Omid; McGee, Heather; Murphy, William J; Crittenden, Marka R.; Gough, Michael J.

In: International Journal of Radiation Oncology Biology Physics, Vol. 99, No. 2, 01.10.2017, p. 362-373.

Research output: Contribution to journalReview article

Baird, Jason R. ; Monjazeb, Arta M ; Shah, Omid ; McGee, Heather ; Murphy, William J ; Crittenden, Marka R. ; Gough, Michael J. / Stimulating Innate Immunity to Enhance Radiation Therapy–Induced Tumor Control. In: International Journal of Radiation Oncology Biology Physics. 2017 ; Vol. 99, No. 2. pp. 362-373.
@article{9656df4284f9454fadaf2f1c338289f6,
title = "Stimulating Innate Immunity to Enhance Radiation Therapy–Induced Tumor Control",
abstract = "Novel ligands that target Toll-like receptors and other innate recognition pathways represent a potent strategy for modulating innate immunity to generate antitumor immunity. Although many of the current clinically successful immunotherapies target adaptive T-cell responses, both preclinical and clinical studies suggest that adjuvants have the potential to enhance the scope and efficacy of cancer immunotherapy. Radiation may be a particularly good partner to combine with innate immune therapies, because it is a highly efficient means to kill cancer cells but may fail to send the appropriate inflammatory signals needed to act as an efficient endogenous vaccine. This may explain why although radiation therapy is a highly used cancer treatment, true abscopal effects—regression of disease outside the field without additional systemic therapy—are extremely rare. This review focuses on efforts to combine innate immune stimuli as adjuvants with radiation, creating a distinct and complementary approach from T cell–targeted therapies to enhance antitumor immunity.",
author = "Baird, {Jason R.} and Monjazeb, {Arta M} and Omid Shah and Heather McGee and Murphy, {William J} and Crittenden, {Marka R.} and Gough, {Michael J.}",
year = "2017",
month = "10",
day = "1",
doi = "10.1016/j.ijrobp.2017.04.014",
language = "English (US)",
volume = "99",
pages = "362--373",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Stimulating Innate Immunity to Enhance Radiation Therapy–Induced Tumor Control

AU - Baird, Jason R.

AU - Monjazeb, Arta M

AU - Shah, Omid

AU - McGee, Heather

AU - Murphy, William J

AU - Crittenden, Marka R.

AU - Gough, Michael J.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Novel ligands that target Toll-like receptors and other innate recognition pathways represent a potent strategy for modulating innate immunity to generate antitumor immunity. Although many of the current clinically successful immunotherapies target adaptive T-cell responses, both preclinical and clinical studies suggest that adjuvants have the potential to enhance the scope and efficacy of cancer immunotherapy. Radiation may be a particularly good partner to combine with innate immune therapies, because it is a highly efficient means to kill cancer cells but may fail to send the appropriate inflammatory signals needed to act as an efficient endogenous vaccine. This may explain why although radiation therapy is a highly used cancer treatment, true abscopal effects—regression of disease outside the field without additional systemic therapy—are extremely rare. This review focuses on efforts to combine innate immune stimuli as adjuvants with radiation, creating a distinct and complementary approach from T cell–targeted therapies to enhance antitumor immunity.

AB - Novel ligands that target Toll-like receptors and other innate recognition pathways represent a potent strategy for modulating innate immunity to generate antitumor immunity. Although many of the current clinically successful immunotherapies target adaptive T-cell responses, both preclinical and clinical studies suggest that adjuvants have the potential to enhance the scope and efficacy of cancer immunotherapy. Radiation may be a particularly good partner to combine with innate immune therapies, because it is a highly efficient means to kill cancer cells but may fail to send the appropriate inflammatory signals needed to act as an efficient endogenous vaccine. This may explain why although radiation therapy is a highly used cancer treatment, true abscopal effects—regression of disease outside the field without additional systemic therapy—are extremely rare. This review focuses on efforts to combine innate immune stimuli as adjuvants with radiation, creating a distinct and complementary approach from T cell–targeted therapies to enhance antitumor immunity.

UR - http://www.scopus.com/inward/record.url?scp=85028727836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028727836&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2017.04.014

DO - 10.1016/j.ijrobp.2017.04.014

M3 - Review article

C2 - 28871985

AN - SCOPUS:85028727836

VL - 99

SP - 362

EP - 373

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -